<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/706EFA5D-AC76-45A1-ABC6-7F37B38251A6"><gtr:id>706EFA5D-AC76-45A1-ABC6-7F37B38251A6</gtr:id><gtr:firstName>Anna-maria</gtr:firstName><gtr:surname>Geretti</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4022124B-F53A-438E-AAA6-F7C75C17CD04"><gtr:id>4022124B-F53A-438E-AAA6-F7C75C17CD04</gtr:id><gtr:firstName>Philippa</gtr:firstName><gtr:surname>Easterbrook</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9E66CD83-291E-41BB-92E3-1881619C3922"><gtr:id>9E66CD83-291E-41BB-92E3-1881619C3922</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:surname>Fenton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AC19B82E-3039-49B7-B5D7-4E86B96B08C4"><gtr:id>AC19B82E-3039-49B7-B5D7-4E86B96B08C4</gtr:id><gtr:firstName>Barry</gtr:firstName><gtr:surname>Peters</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/586662E4-394A-4579-B9E1-8402D712887A"><gtr:id>586662E4-394A-4579-B9E1-8402D712887A</gtr:id><gtr:firstName>Geoff</gtr:firstName><gtr:surname>Garnett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0200585"><gtr:id>9561B929-C893-401D-AB2F-2A03107D8BF3</gtr:id><gtr:title>Impact of HIV among black Caribbeans in South London: A sociodemographic, behavioural and laboratory study in black Cari</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200585</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>170340</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Center for HIV/AIDS Vaccine Immunology (CHAVI)</gtr:department><gtr:description>CHAVI</gtr:description><gtr:id>01C2AC8F-3AE4-45F9-A2A2-38B479C59E0A</gtr:id><gtr:impact>please refer to publications</gtr:impact><gtr:outcomeId>RteTL6rGMPg-1</gtr:outcomeId><gtr:partnerContribution>scientific interchange</gtr:partnerContribution><gtr:piContribution>provide critical clinical samples from HIV patients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>developing WFDC1/ps20 as a novel biomarker in HIV infection</gtr:description><gtr:id>BC85F681-87BB-4AE8-840D-D169DB605B22</gtr:id><gtr:impact>17942534 Alvarez R (Jan, 2008) WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection., Journal of virology 82, 1, 471-86</gtr:impact><gtr:outcomeId>DXp7tTaHNhy-1</gtr:outcomeId><gtr:piContribution>provide patient samples and scholarly input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Community Advisory Group Meetings and newsletters</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>B594CA81-AFDE-4962-A33D-17A9A8D9CCA3</gtr:id><gtr:impact>Community Advisory Group (CAG) is a multidisciplinary group of 10 members of the black Caribbean community who work in: sexual health promotion; sexual health community outreach; sexual health policy development; advocacy for homosexual Caribbean men; and HIV/AIDS research. The CAG also comprised a religious leader active in the South London black Caribbean community

The objectives of the CAG were to: (i) adapt study design and procedure in order to maximise its acceptability within the target population, particularly through review of the questionnaire; (ii) provide a two-way channel of communication between the black Caribbean population and researchers, particularly through informing community members of the project, communicating their actual and potential concerns, and disseminating the study's results; (iii) assist in developing further projects and health promotion interventions for the black Caribbean population</gtr:impact><gtr:outcomeId>305F8E417CB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Expert Advisory Group on AIDS (EAGA), Department of Health</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>AFB9D6CA-1293-4D1D-8D72-24D33A7437F3</gtr:id><gtr:impact>HIV in Black Caribbeans in the UK: An Emerging Epidemic? (Oral presentation Professor Philippa Easterbrook), June 2006

None yet</gtr:impact><gtr:outcomeId>4F1FB520952</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Caribbean Sexual Health Forum</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>79041517-535C-4554-B8F2-0DFF09DF89AB</gtr:id><gtr:impact>Caribbean Sexual Health Forum - approximately 120 people including other researchers, members of sexual health outreach services, NHS staff and interested members of the public. Organised by Health First

Refined questionnaire</gtr:impact><gtr:outcomeId>D561F4852FD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>18653</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHAVI</gtr:description><gtr:end>2006-06-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>2385B7D4-4AAB-41D9-B6DD-40546FF1ED0E</gtr:id><gtr:outcomeId>D2K247fYKSy0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>122976</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre for HIV/AIDS Vaccine Immunology CHAVI Protocol 008 Core B</gtr:description><gtr:end>2009-06-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>5C8AE15A-2DF1-48EC-8E10-DE1DB4958D89</gtr:id><gtr:outcomeId>jkcXJLtNeXP0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>92465</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHAVI 2</gtr:description><gtr:end>2008-06-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>8B6B0DAB-3D28-460F-9945-80E67C38036B</gtr:id><gtr:outcomeId>oXD2r8ePx820</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>225673</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Epidemiology of HIV-Related Immune Reconstitution Inflammatory Syndrome in South Africa</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F324888F-930A-4C5E-8EA0-161CCF50A4D0</gtr:id><gtr:outcomeId>iGWtKqgzPwH0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>31647</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre for HIV/AIDS Vaccine Immunology CHAVI Protocol 008 Core B</gtr:description><gtr:end>2008-12-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>B831B904-FAAD-431D-B40B-528DDA0DE3C2</gtr:id><gtr:outcomeId>puA4zutyVea0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20290</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Epidemiology and pathogenesis of HIV Immune Reconstitution Syndrome in sub-Saharan Africa and genetics of HIV-1 long-term non-progression</gtr:description><gtr:end>2008-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>C0F9F383-06D6-471F-A2F2-C7D72DE80975</gtr:id><gtr:outcomeId>PkMmYwzGYuN0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5578</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Abbott UK</gtr:department><gtr:description>A phase 3 randomised, open-label study of Lopinavir/ ritonavir tablets 800/200 mg once daily versus 400/100 mg twice daily when co-administered with nucleoside/Nucleotide reverse transcriptase inhibitors in antiretroviral-experienced HIV-1 infected subjects</gtr:description><gtr:end>2008-05-02</gtr:end><gtr:fundingOrg>Abbott</gtr:fundingOrg><gtr:id>B47EBE84-F7A1-4F22-9DF7-D84725FADF2F</gtr:id><gtr:outcomeId>RrdmSKAfr3P0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48768</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHAVI 2</gtr:description><gtr:end>2008-12-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>8FFD5134-206A-4EB2-ACA8-DFDAE4DC4C65</gtr:id><gtr:outcomeId>akGJieM915D0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56871</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHAVI 2</gtr:description><gtr:end>2007-06-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>998A7A40-2751-4492-8D89-393F287E0019</gtr:id><gtr:outcomeId>GjcWPBNbynX0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Epidemiology of Immune Reconstitution Inflammatory Syndrome</gtr:description><gtr:end>2009-08-02</gtr:end><gtr:fundingOrg>British Society for Antimicrobial Chemotherapy</gtr:fundingOrg><gtr:id>547E1A0C-B316-477F-853A-3CE009069D03</gtr:id><gtr:outcomeId>Xj7NYkBozR30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46001</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Epidemiology and Immunogenetics of Immune Reconstitution Inflammatory Syndrome (Doris Duke Foundation via Friends of King's College London (USA)</gtr:description><gtr:end>2007-07-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>D48BA8AF-F3DA-49B8-B397-D81DC82177B3</gtr:id><gtr:outcomeId>FHqKcmpr1Mh0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7184</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A Phase III randomised, double-blinded, placebo controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator selected OBR in HIV-1 infected</gtr:description><gtr:end>2007-02-02</gtr:end><gtr:fundingOrg>Janssen Research &amp; Development</gtr:fundingOrg><gtr:id>4665F2B5-8D28-4B6E-B324-5C12BAA0019A</gtr:id><gtr:outcomeId>ZW9Xhpgw5qY0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2006-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AAD5B94F-632F-43D5-AC46-A2B5D70534E7</gtr:id><gtr:title>Predictors of renal outcome in HIV-associated nephropathy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e65fa8c83ae955be691251a1f8d9da9"><gtr:id>9e65fa8c83ae955be691251a1f8d9da9</gtr:id><gtr:otherNames>Post FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>QLCg9bjJqoh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4ACD4C9-8428-453C-8DCA-03A5B0109E64</gtr:id><gtr:title>Coping with HIV: Caribbean people in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Qualitative health research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f961a2bc27811a057a568146e7aa9a"><gtr:id>70f961a2bc27811a057a568146e7aa9a</gtr:id><gtr:otherNames>Anderson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1049-7323</gtr:issn><gtr:outcomeId>VZZMVCPrgmB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AED5BFD3-F6D8-4392-8331-DD3061349817</gtr:id><gtr:title>Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2a977e7885826608671278adbb244e7"><gtr:id>a2a977e7885826608671278adbb244e7</gtr:id><gtr:otherNames>Nakanjako D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>PfF7ZXfzcxG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C8D62FF-C5C6-485B-A7BD-8E96B1C5B937</gtr:id><gtr:title>Virological response to initial antiretroviral regimens containing abacavir or tenofovir.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>EUkpf5tEp2t</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52760DE0-4A86-4E8D-8633-91924C760714</gtr:id><gtr:title>Data linkage reduces loss to follow-up in an observational HIV cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/714c11cae3bdf9319cae1a059307588e"><gtr:id>714c11cae3bdf9319cae1a059307588e</gtr:id><gtr:otherNames>Hill T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>puFcXPmX4Ye</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F6B07D5-30D4-4E0E-B732-A90FCB903976</gtr:id><gtr:title>Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85a60e5066ab5ec74048e84f9e035c69"><gtr:id>85a60e5066ab5ec74048e84f9e035c69</gtr:id><gtr:otherNames>Grant AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>ANam8ofoe2k</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E8A20C8-E113-49D4-A711-223F0D9FFA7F</gtr:id><gtr:title>Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c5153a5bcbf25ee1ed0265ff6c84dc3"><gtr:id>2c5153a5bcbf25ee1ed0265ff6c84dc3</gtr:id><gtr:otherNames>Ratnam I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>qMQmQh5XPJv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF75E01F-2312-46FB-9E51-7BFA2421E609</gtr:id><gtr:title>The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b4f4f0e21733962eec60068490aaae8"><gtr:id>8b4f4f0e21733962eec60068490aaae8</gtr:id><gtr:otherNames>Sabin CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>YbvFbSMwdon</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B8D544E-D3B4-4ED5-B3AB-80901A2B67C6</gtr:id><gtr:title>Is 1 alanine transaminase &amp;gt;200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>W6k8gPQvHv2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EA5F643-4F8A-4884-A731-C4928BF4EF02</gtr:id><gtr:title>Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24c1aa893c155e258dfaadc492353fb5"><gtr:id>24c1aa893c155e258dfaadc492353fb5</gtr:id><gtr:otherNames>Walmsley SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>ovFHmAFFt19</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25390EDA-002F-4529-9DD4-760F5ED2A10B</gtr:id><gtr:title>Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2bb0b05db50d7622ad34646ff7bfe15"><gtr:id>a2bb0b05db50d7622ad34646ff7bfe15</gtr:id><gtr:otherNames>Easterbrook PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>QtY5vWEytpx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29CA2DA6-E8F5-4B98-8A1A-AB34402A7D99</gtr:id><gtr:title>Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c038bff81d22f1b254cc1f518eea7a74"><gtr:id>c038bff81d22f1b254cc1f518eea7a74</gtr:id><gtr:otherNames>Thananchai H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>PfNt2gB8dKr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90E25329-494E-4050-BDCA-1C232417C2B5</gtr:id><gtr:title>A whole-genome association study of major determinants for host control of HIV-1.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b430cb6cad42d67be5e4807f7cf17e7"><gtr:id>9b430cb6cad42d67be5e4807f7cf17e7</gtr:id><gtr:otherNames>Fellay J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>AUyKq94cV6z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A0D9153-7A09-4619-B4F2-E2D6C000DB38</gtr:id><gtr:title>Factors influencing lopinavir and atazanavir plasma concentration.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>PVkxLwcn8o5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3ACA9502-01EF-4DA8-BDA2-A48F769D3439</gtr:id><gtr:title>Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c33c411ca28c0a937d2f7e2ccf2775a7"><gtr:id>c33c411ca28c0a937d2f7e2ccf2775a7</gtr:id><gtr:otherNames>Gordin FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>Mw1DHVBUVoF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5AABFEE-8B86-4BE5-8896-E1A7C176CAF7</gtr:id><gtr:title>Occupational exposure to HIV and the use of post-exposure prophylaxis.</gtr:title><gtr:parentPublicationTitle>Occupational medicine (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0962-7480</gtr:issn><gtr:outcomeId>b6hV6p53vir</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA1696BA-1CF1-4CFA-A7C5-795A989DF76C</gtr:id><gtr:title>Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d90882e650eb8a23e2bf5788035224d2"><gtr:id>d90882e650eb8a23e2bf5788035224d2</gtr:id><gtr:otherNames>Benzie AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>JPudL4jJqHg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9CC035D-B859-438F-81C8-3CA7B380791A</gtr:id><gtr:title>WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b5cc624bad12d0c96969bf1c791498c"><gtr:id>8b5cc624bad12d0c96969bf1c791498c</gtr:id><gtr:otherNames>Alvarez R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>cViMYy5LDGt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>353F6484-5BA9-4655-B222-353014859072</gtr:id><gtr:title>HIV drug resistance in HIV-infected children.</gtr:title><gtr:parentPublicationTitle>Jornal de pediatria</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd7707080b29413de3ab82c80ee6f1d"><gtr:id>bbd7707080b29413de3ab82c80ee6f1d</gtr:id><gtr:otherNames>Easterbrook P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-7557</gtr:issn><gtr:outcomeId>JyYuUAZysXV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1929D284-2272-4D90-BCBF-FC7925D67429</gtr:id><gtr:title>Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a25a29714d4d1b458e29e56d0e5c8fe"><gtr:id>1a25a29714d4d1b458e29e56d0e5c8fe</gtr:id><gtr:otherNames>Nandi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>H6ctLNC8Q5w</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B4B1532-D737-4D0D-AA75-607179D7A677</gtr:id><gtr:title>Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67bf0438df67a346b08f5f6dcc5e0e0b"><gtr:id>67bf0438df67a346b08f5f6dcc5e0e0b</gtr:id><gtr:otherNames>Haddow LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>Dum2cUKSgNG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB335C06-1BB4-4AD6-A382-35F0567FDC3E</gtr:id><gtr:title>Characterization of an HLA-C-restricted CTL response in chronic HIV infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/193c31d7dd0cbcc9e1cc55671bfe06d2"><gtr:id>193c31d7dd0cbcc9e1cc55671bfe06d2</gtr:id><gtr:otherNames>Makadzange AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>aYqHtQsLrxi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0407CA1F-0526-4331-BD26-C3750DABB8D9</gtr:id><gtr:title>Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80ef2fc5722c8a9f01840c09081cd416"><gtr:id>80ef2fc5722c8a9f01840c09081cd416</gtr:id><gtr:otherNames>Castelnuovo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>WPR7iMBnLR6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37FDBEDC-1744-4B54-AA9F-F040ED744AF0</gtr:id><gtr:title>Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c2dc3cb91c8d7e7089e83ba9820a2f"><gtr:id>03c2dc3cb91c8d7e7089e83ba9820a2f</gtr:id><gtr:otherNames>Bansi LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>sj8TKj2Azpi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>125E43C4-8742-4844-8D8D-367E8B1E19F9</gtr:id><gtr:title>Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67bf0438df67a346b08f5f6dcc5e0e0b"><gtr:id>67bf0438df67a346b08f5f6dcc5e0e0b</gtr:id><gtr:otherNames>Haddow LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>L1wHUUqbejX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8A54C70-6B95-4C3A-9554-E48E835A1666</gtr:id><gtr:title>Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28a5c1ff15012815b47d152504b4c3b8"><gtr:id>28a5c1ff15012815b47d152504b4c3b8</gtr:id><gtr:otherNames>Bansi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>hvzgA2XhXDt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01CF9FAF-39D7-4CDB-958C-76C14EA4FF8E</gtr:id><gtr:title>Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>TQrcmXpS7Pj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCBB1502-6CBC-46BB-A295-3C14D01BB9B9</gtr:id><gtr:title>Sexual health and HIV in travellers and expatriates.</gtr:title><gtr:parentPublicationTitle>Occupational medicine (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0962-7480</gtr:issn><gtr:outcomeId>Ni5TcwRxvBd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50B6447E-6589-425F-A56C-0B76B54D6E93</gtr:id><gtr:title>Is antiretroviral therapy associated with symptom prevalence and burden?</gtr:title><gtr:parentPublicationTitle>International journal of STD &amp; AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edaa7ad6a9b79774892fe9f893534d69"><gtr:id>edaa7ad6a9b79774892fe9f893534d69</gtr:id><gtr:otherNames>Harding R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0956-4624</gtr:issn><gtr:outcomeId>WExj2TevQWF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7DF46A3-C114-4F6C-958D-0845BF50A256</gtr:id><gtr:title>The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afdf783165c02c37a71e5e1baef67b12"><gtr:id>afdf783165c02c37a71e5e1baef67b12</gtr:id><gtr:otherNames>Turner J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>kRZhwHGtdq7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>754B8540-B8AE-4A17-9D3B-14DB4874FC2F</gtr:id><gtr:title>High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddc2382b2096c9e8d20001d831de338e"><gtr:id>ddc2382b2096c9e8d20001d831de338e</gtr:id><gtr:otherNames>Gerver SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>EPnavsYYXFP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F3ECE11-02E3-4D7D-ABC0-705D36C5136D</gtr:id><gtr:title>CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cda3c874d6e33c2fafcfea247a9eedbe"><gtr:id>cda3c874d6e33c2fafcfea247a9eedbe</gtr:id><gtr:otherNames>Bower M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>TgAEuFfegyu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BFEEF44-0D6D-451E-9A01-931C9834F099</gtr:id><gtr:title>Sexual health: overview.</gtr:title><gtr:parentPublicationTitle>Occupational medicine (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd7707080b29413de3ab82c80ee6f1d"><gtr:id>bbd7707080b29413de3ab82c80ee6f1d</gtr:id><gtr:otherNames>Easterbrook P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0962-7480</gtr:issn><gtr:outcomeId>GHV9zKCdHQJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A215750D-B526-4E69-9BAC-8DDC47244398</gtr:id><gtr:title>Strong TCR conservation and altered T cell cross-reactivity characterize a B*57-restricted immune response in HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f5491b386d455aa4032571d48e83937"><gtr:id>6f5491b386d455aa4032571d48e83937</gtr:id><gtr:otherNames>Gillespie GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pPPxwGje9bx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6EEDF74-1BBC-4D25-9C88-767DEC92533C</gtr:id><gtr:title>Cerebral toxoplasmosis in a middle-aged man as first presentation of primary immunodeficiency due to a hypomorphic mutation in the CD40 ligand gene.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af5f425361767c3c716b509a03cb000e"><gtr:id>af5f425361767c3c716b509a03cb000e</gtr:id><gtr:otherNames>Yong PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>QoSjV3e2zeY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB32B4B2-84F4-4B87-A536-B6818C103A8A</gtr:id><gtr:title>HIV immune reconstitution syndrome in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2bb0b05db50d7622ad34646ff7bfe15"><gtr:id>a2bb0b05db50d7622ad34646ff7bfe15</gtr:id><gtr:otherNames>Easterbrook PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>UveKJ6j6ctD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>519D7D24-5A23-4406-A84D-3648CABE4649</gtr:id><gtr:title>Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2bb0b05db50d7622ad34646ff7bfe15"><gtr:id>a2bb0b05db50d7622ad34646ff7bfe15</gtr:id><gtr:otherNames>Easterbrook PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>VRabQA51kmA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C2376CD-5202-442E-BE23-681B741272F0</gtr:id><gtr:title>HIV/AIDS-related stigma and discrimination: accounts of HIV-positive Caribbean people in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Social science &amp; medicine (1982)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f961a2bc27811a057a568146e7aa9a"><gtr:id>70f961a2bc27811a057a568146e7aa9a</gtr:id><gtr:otherNames>Anderson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0277-9536</gtr:issn><gtr:outcomeId>exMMpseGSoV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F935704-6181-4B8F-BF7A-3F6F9CF73E5C</gtr:id><gtr:title>Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda.</gtr:title><gtr:parentPublicationTitle>BMC health services research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7762bb9f26c2a7f1dbf33afad3c6b83"><gtr:id>a7762bb9f26c2a7f1dbf33afad3c6b83</gtr:id><gtr:otherNames>Babigumira JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1472-6963</gtr:issn><gtr:outcomeId>HBgEfj9fkLe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EED40AF-BEA9-43FB-BEBF-1E914DA8FB56</gtr:id><gtr:title>Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>gacCTmp4Kni</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B230005-832B-45BE-824A-91B83D112B7E</gtr:id><gtr:title>Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>WCWe4NmsFWp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A470E0E-BA74-4FC4-8D4B-BE876AC65145</gtr:id><gtr:title>The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.</gtr:title><gtr:parentPublicationTitle>AIDS reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42769adb31ed8d2882873c9f5819d8c3"><gtr:id>42769adb31ed8d2882873c9f5819d8c3</gtr:id><gtr:otherNames>Sendagire H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1139-6121</gtr:issn><gtr:outcomeId>abvnYuxwRbg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>624F5668-8845-4F2B-AECB-D20428E893BB</gtr:id><gtr:title>Liminal identities: Caribbean men who have sex with men in London, UK.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f961a2bc27811a057a568146e7aa9a"><gtr:id>70f961a2bc27811a057a568146e7aa9a</gtr:id><gtr:otherNames>Anderson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>dneQbAbJsfi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31FF8531-368A-4608-BD03-624B0B0DE787</gtr:id><gtr:title>Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67bf0438df67a346b08f5f6dcc5e0e0b"><gtr:id>67bf0438df67a346b08f5f6dcc5e0e0b</gtr:id><gtr:otherNames>Haddow LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pULRsFPzum5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>041BBE73-972B-47BE-9BE8-B1C8F7B158E1</gtr:id><gtr:title>Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f9f2f726c29e3ec6d0a6d004eec899b"><gtr:id>0f9f2f726c29e3ec6d0a6d004eec899b</gtr:id><gtr:otherNames>Porter K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>Z2Bgx3hGRTB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74AEDF25-8F92-4EB0-9180-D294352FCEF8</gtr:id><gtr:title>Evidence for onward transmission of HIV-1 non-B subtype strains in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c27b2a4caf70bef96a1422982922b510"><gtr:id>c27b2a4caf70bef96a1422982922b510</gtr:id><gtr:otherNames>Aggarwal I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>MxKDRQ65q43</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF54E63A-A7D6-449F-8E8A-C2E3D65A70B1</gtr:id><gtr:title>Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8ddf4eb8bd657dafa0f77c1c74dd383"><gtr:id>c8ddf4eb8bd657dafa0f77c1c74dd383</gtr:id><gtr:otherNames>United Kingdom Collaborative HIV Cohort Study</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>TpxvpY14aPu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>859D9AE1-4F50-47E9-8051-5F3DD8455C6A</gtr:id><gtr:title>&amp;quot;It took a piece of me&amp;quot;: initial responses to a positive HIV diagnosis by Caribbean people in the UK.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f961a2bc27811a057a568146e7aa9a"><gtr:id>70f961a2bc27811a057a568146e7aa9a</gtr:id><gtr:otherNames>Anderson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>C9MHhYcDUHG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C870839-A06C-4D7E-ABC6-EF0787C9D02C</gtr:id><gtr:title>Systematic review of the empirical evidence of study publication bias and outcome reporting bias.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92032a2603eb4aabc998973c797e3802"><gtr:id>92032a2603eb4aabc998973c797e3802</gtr:id><gtr:otherNames>Dwan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>CcEgKSeKRvg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCD517A7-059A-4656-BACD-B3EB79D17A07</gtr:id><gtr:title>Immune reconstitution disease associated with mycobacterial infections.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/007c19ec1837bec65f308e1d0dd67786"><gtr:id>007c19ec1837bec65f308e1d0dd67786</gtr:id><gtr:otherNames>Lawn SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>iA5xcW4uYzy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D98C75BC-4C60-4AEC-86FD-027AE4A13D31</gtr:id><gtr:title>Common genetic variation and the control of HIV-1 in humans.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b430cb6cad42d67be5e4807f7cf17e7"><gtr:id>9b430cb6cad42d67be5e4807f7cf17e7</gtr:id><gtr:otherNames>Fellay J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>a1iVtkEjn8B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D86A3E63-C2AE-434B-BEFE-1F8C24A51269</gtr:id><gtr:title>CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>MffUtnD9EzD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E009C291-2B95-4891-A5BB-4BE2FBB38708</gtr:id><gtr:title>Identification of a novel HLA B*57 restricted cytotoxic T-lymphocyte epitope within HIV-1 rev.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/193c31d7dd0cbcc9e1cc55671bfe06d2"><gtr:id>193c31d7dd0cbcc9e1cc55671bfe06d2</gtr:id><gtr:otherNames>Makadzange AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>r7ncDL8AMaC</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200585</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>2472941E-25F2-45EC-A735-3C0872CE6B26</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>2.3  Psychological, social and economic factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>